To determine whether Nrf2 or Cripto-1 plays a pivotal role in breast cancer stemness in MDA-MB-231 cells, the Nrf2 inhibitor, brusatol, was used to evaluate the expression of Cripto-1 and the other stemness-related proteins. Here, NFE2L2 is linked to breast cancer.